Activation by toll-like receptor 7 (TLR7) ligand reverses pDC immunosuppressive function to such an extent that their administration to melanoma patients induces tumor-specific CD4+ and CD8+ T-cell responses (16, 17). The gene discussed is CD8A; the disease is melanoma.